Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

Launched by EMD SERONO · Feb 13, 2006

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Greater than or equal to 18 years of age
• • Has relapsing-remitting MS
• • Are willing and able to comply with the protocol for the duration of the study
• Exclusion Criteria:
• • Has significant leukopenia/lymphopenia (white blood cell count less than (\<) 0.5 times the lower limit of normal)
• • Has elevated liver function tests (aspartate aminotransferase \[AST\], Alanine transaminase \[ALT\], or alkaline phosphatase greater than (\>) 2 times the upper limit of normal or total bilirubin \> 1.5 times the upper limit of normal)
• • Has an allergy to human serum albumin or mannitol
• • Had treatment with an investigational product or procedure within 3 months
• • Has the presence of systemic disease or abnormal laboratory findings that might interfere with subject safety, compliance or evaluation of the condition under study
• • Has concomitant use of Avonex®, Betaseron®, Copaxone®, or Novantrone®